Skip to content
The People's CodeSearch
Menu

Changes to the Code

S. 4472 · Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 ·

Passed the Senate · step 3 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

42 U.S.C. § 280g–7b HHS public-private partnership for rare neurodegenerative diseases

+2 −2Shown
More for 42 U.S.C. § 280g–7b
Read § 280g–7bOnly this section
2 changes the bill asks for here, 2 carried out
  1. Carried out:

    in subsection (a), in the matter preceding paragraph (1), by striking amytrophic and inserting amyotrophic; and

  2. Carried out:

    in subsection (b)(3)(A)(iii), by striking rational.

§ 280g–7b(a)

WhereMarkThe Code nowMarkAs the bill would leave it
§ 280g–7b. HHS public-private partnership for rare neurodegenerative diseases§ 280g–7b. HHS public-private partnership for rare neurodegenerative diseases
(a)(a) Establishment(a) Establishment
Not later than one year after December 23, 2021, the Secretary of Health and Human Services (referred to in this section as the “Secretary”) shall establish and implement a Public-Private Partnership for Neurodegenerative Diseases between the National Institutes of Health, the Food and Drug Administration, and one or more eligible entities (to be known and referred to in this section as the “Partnership”) through cooperative agreements, contracts, or other appropriate mechanisms with such eligible entities, for the purpose of advancing the understanding of neurodegenerative diseases and fostering the development of treatments for [struck: amytrophic] lateral sclerosis and other rare neurodegenerative diseases. The Partnership shall—Not later than one year after December 23, 2021, the Secretary of Health and Human Services (referred to in this section as the “Secretary”) shall establish and implement a Public-Private Partnership for Neurodegenerative Diseases between the National Institutes of Health, the Food and Drug Administration, and one or more eligible entities (to be known and referred to in this section as the “Partnership”) through cooperative agreements, contracts, or other appropriate mechanisms with such eligible entities, for the purpose of advancing the understanding of neurodegenerative diseases and fostering the development of treatments for [inserted: amyotrophic] lateral sclerosis and other rare neurodegenerative diseases. The Partnership shall—
(a)(1)(1) (1)
establish partnerships and consortia with other public and private entities and individuals with expertise in amyotrophic lateral sclerosis and other rare neurodegenerative diseases for the purposes described in this subsection;establish partnerships and consortia with other public and private entities and individuals with expertise in amyotrophic lateral sclerosis and other rare neurodegenerative diseases for the purposes described in this subsection;
(a)(2)(2) (2)
focus on advancing regulatory science and scientific research that will support and accelerate the development and review of drugs for patients with amyotrophic lateral sclerosis and other rare neurodegenerative diseases; andfocus on advancing regulatory science and scientific research that will support and accelerate the development and review of drugs for patients with amyotrophic lateral sclerosis and other rare neurodegenerative diseases; and

§ 280g–7b(b)Eligible entity(3)–(4)

(a)(3)–(b)(3) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(3)(A)(ii)(ii) (ii)
to identify molecular targets for neurodegenerative diseases; andto identify molecular targets for neurodegenerative diseases; and
(3)(A)(iii)(iii) (iii)
to increase efficiency, predictability, and productivity of clinical development of therapies, including advancement of [struck: rational ]therapeutic development and establishment of clinical trial networks; andto increase efficiency, predictability, and productivity of clinical development of therapies, including advancement of therapeutic development and establishment of clinical trial networks; and
(3)(B)(B) (B)
securing funding for the Partnership from Federal and non-Federal governmental sources, foundations, and private individuals; andsecuring funding for the Partnership from Federal and non-Federal governmental sources, foundations, and private individuals; and
(4)(4) (4)
provides an assurance that the entity will not accept funding for a Partnership project from any organization that manufactures or distributes products regulated by the Food and Drug Administration unless the entity provides assurances in its agreement with the Secretary that the results of the project will not be influenced by any source of funding.provides an assurance that the entity will not accept funding for a Partnership project from any organization that manufactures or distributes products regulated by the Food and Drug Administration unless the entity provides assurances in its agreement with the Secretary that the results of the project will not be influenced by any source of funding.

Rest of § 280g–7b unchanged

Step through the changes